DelveInsight’s “C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the C-MET+ NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the C-MET+ NSCLC therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the c-MET-NSCLC Treatment Landscape @ https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight

Key Takeaways from the c-MET-NSCLC Pipeline Report

• On June 26, 2026- AbbVie initiated a phase 2 study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio.
• On June 05, 2026- Beijing Pearl Biotechnology Limited Liability Company conducted a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation. PLB1001 will be administrated 200mg twice daily. The treatment will be discontinued for the patients who experience disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent. A cycle of study treatment will be defined as 28 days of continuous dosing. The study includes 4 cohorts.
• DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for c-MET-NSCLC treatment.
• The leading c-MET-NSCLC Companies such as AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
• Promising C-MET NSCLC Therapies such as Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others.

Download for updates and be a part of the revolution in cancer care @ c-MET NSCLC Clinical Trials Assessment

C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Overview

The role of the c-mesenchymal-epithelial transition factor (C-MET) signaling pathway in tumor progression and invasion has been extensively studied. C-MET inhibitors have shown anti-tumor activity in Non-Small Cell Lung Cancer both in preclinical and in clinical trials. However, given the molecular heterogeneity of Non-Small Cell Lung Cancer, it is likely that only a specific subset of Non-Small Cell Lung Cancer Patients will benefit from c-MET Inhibitors. Emerging data also suggest that MET Inhibitors in combination with EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors) may have a role in therapy for both EGFR-TKI resistant and EGFR-TKI naïve patients. c-Met is known to be overexpressed, mutated and gene amplified, specifically in NSCLC, and has also been implicated in the development of resistance against other small-molecule inhibitors (e.g. EGFR).

c-MET NSCLC Emerging Drugs Profile

• JNJ-61186372: Janssen Research & Development, LLC

JNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations and amplifications. The production and development of the antibody followed Janssen’s licensing agreement with Genmab for use of its DuoBody technology platform. According to the company, JNJ-6372 is a novel bispecific antibody that has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies.

• PLB1001 – Beijing Pearl Biotechnology Limited Liability Company

PLB1001 is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, PLB1001 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

The C-MET NSCLC Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of C-MET NSCLC with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for C-MET NSCLC Treatment.
• C-MET NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• C-MET NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the C-MET NSCLC market.

Learn more about c-MET NSCLC Drugs opportunities in our groundbreaking Research and development projects @ c-MET NSCLC Unmet Needs

c-MET NSCLC Companies

AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.

C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intramuscular
• Intratumoral
• Intravenous
• Molecule Type

c-MET NSCLC Products have been categorized under various Molecule types such as

• Gene therapies
• Bispecific antibodies
• Immunotherapies
• Monoclonal antibodies
• Small molecules
• Product Type

Stay informed about how we’re transforming the future of oncology @ c-MET NSCLC Market Drivers and Barriers, and Future Perspectives

Scope of the c-MET NSCLC Pipeline Report

• Coverage- Global
• c-MET NSCLC Companies- AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
• C-MET NSCLC Therapies- Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others.
• c-MET NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• c-MET NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of c-MET NSCLC Pipeline on our website @ c-MET NSCLC Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Collaboration Deals
9. Mid Stage Products (Phase II)
10. Telisotuzumab: AbbVie
11. PLB1001: Beijing Pearl Biotechnology Limited Liability Company
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. JNJ-61186372: Janssen Research & Development, LLC
15. Drug profiles in the detailed report…..
16. Pre-clinical and Discovery Stage Products
17. Drug profiles in the detailed report…..
18. Inactive Products
19. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
20. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Products
21. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Unmet Needs
22. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Market Drivers and Barriers
23. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Future Perspectives and Conclusion
24. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Analyst Views
25. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight